U.S., Oct. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07857616) titled 'SI-B036-ST-101 in Advanced/Metastatic Solid Tumors' on Sept. 22.
Brief Summary: The objective of the study is to evaluate the safety and tolerability of SI-B036 in participants with solid tumors who have received at least one prior line of therapy for advanced disease.
Study Start Date: Sept., 2026
Study Type: INTERVENTIONAL
Condition:
Locally Advanced /Metastatic Solid Tumors
Locally Advanced / Metastatic Solid Tumors
Metastatic Solid Cancers
Non Small Cell Lung Cancer
Lung Cancer
Melanoma
Ovarian
NSCLC
Intervention:
DRUG: SI-B036
SI-B036 will be administered on Day 1 by intravenous (IV) infusion every 3 weeks
Recruitment St...